Company intelligence / Profile preview

Cardiosonic

Ownership: Private
Employees: ~17
Development stage: Other

Overview

Cardiosonic has developed the TIVUS™ System, a high-intensity non-focused therapeutic ultrasound catheter designed to perform renal denervation without damaging the arterial endothelium. The device has undergone extensive preclinical testing and multiple human clinical trials targeting resistant hypertension. Initial results have led to CE marking in Europe and ongoing efforts toward regulatory approval elsewhere.

Therapeutic areas: Cardiovascular
Modalities: DeviceTherapeutic ultrasound catheter system
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Cardiosonic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cardiosonic.

Explore the full profile